Showing 13 to 24 of 171 results
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
DLBCL Treatment: High Relapse Rates, Promising Immunotherapies
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, affects around 3,000 people annually in Spain; while 60-70% of patients are cured with initial chemotherapy, 40% relapse, necessitating innovative treatments like CAR-T cell therapy, which offers a 40% cure rate but...
Progress
52% Bias Score
Ovarian Tissue Cryopreservation Enables Conception After Hodgkin's Lymphoma Treatment
36-year-old Sara Rossetti, diagnosed with Hodgkin's lymphoma at 21, successfully conceived a child after undergoing ovarian tissue cryopreservation before chemotherapy, highlighting the procedure's effectiveness and the need for increased accessibility.
Ovarian Tissue Cryopreservation Enables Conception After Hodgkin's Lymphoma Treatment
36-year-old Sara Rossetti, diagnosed with Hodgkin's lymphoma at 21, successfully conceived a child after undergoing ovarian tissue cryopreservation before chemotherapy, highlighting the procedure's effectiveness and the need for increased accessibility.
Progress
44% Bias Score
Glioblastoma Patient Shows No Signs of Cancer After Immunotherapy Treatment
A 43-year-old man, Ben Trotman, diagnosed with glioblastoma in October 2022, is cancer-free following an experimental immunotherapy treatment at University College London Hospital, defying the typical 12-18 month survival rate for this aggressive brain cancer.
Glioblastoma Patient Shows No Signs of Cancer After Immunotherapy Treatment
A 43-year-old man, Ben Trotman, diagnosed with glioblastoma in October 2022, is cancer-free following an experimental immunotherapy treatment at University College London Hospital, defying the typical 12-18 month survival rate for this aggressive brain cancer.
Progress
48% Bias Score
Metastatic Melanoma: Aggressive Treatment Yields Positive Results
Jennifer Frederick, 50, was diagnosed with metastatic malignant melanoma after discovering a lump in her groin; despite aggressive treatment causing severe side effects, scans show major improvement, highlighting advancements in immunotherapy and offering hope for long-term survival.
Metastatic Melanoma: Aggressive Treatment Yields Positive Results
Jennifer Frederick, 50, was diagnosed with metastatic malignant melanoma after discovering a lump in her groin; despite aggressive treatment causing severe side effects, scans show major improvement, highlighting advancements in immunotherapy and offering hope for long-term survival.
Progress
40% Bias Score
German Breast Cancer: Treatment Advancements Drive High Survival Rates
In Germany, approximately 1 in 8 women develop breast cancer, a figure attributed to lifestyle, diet, and environmental factors; however, advancements in treatments like targeted antibodies and immunotherapies have led to 80–90% survival rates across all stages.
German Breast Cancer: Treatment Advancements Drive High Survival Rates
In Germany, approximately 1 in 8 women develop breast cancer, a figure attributed to lifestyle, diet, and environmental factors; however, advancements in treatments like targeted antibodies and immunotherapies have led to 80–90% survival rates across all stages.
Progress
44% Bias Score
Esteve Acquires Caprelsa, Advancing Specialized Therapy Strategy
Esteve, a Barcelona-based pharmaceutical company, announced the acquisition of Caprelsa, a thyroid cancer treatment, from Sanofi on Monday, furthering its strategy to specialize in highly specialized therapies, fueled by a €1 billion investment from Lubea in 2023. This follows several other acquisit...
Esteve Acquires Caprelsa, Advancing Specialized Therapy Strategy
Esteve, a Barcelona-based pharmaceutical company, announced the acquisition of Caprelsa, a thyroid cancer treatment, from Sanofi on Monday, furthering its strategy to specialize in highly specialized therapies, fueled by a €1 billion investment from Lubea in 2023. This follows several other acquisit...
Progress
32% Bias Score
Imprisoned Turkish Mayor's Health Deteriorates Amidst Untreated Cancer
Former Sarıyer Mayor Şükrü Genç, imprisoned in Silivri for alleged DHKP-C financing, is suffering from a critical deterioration of his health due to untreated colon cancer and other illnesses; his lawyer claims his continued detention amounts to a death sentence.
Imprisoned Turkish Mayor's Health Deteriorates Amidst Untreated Cancer
Former Sarıyer Mayor Şükrü Genç, imprisoned in Silivri for alleged DHKP-C financing, is suffering from a critical deterioration of his health due to untreated colon cancer and other illnesses; his lawyer claims his continued detention amounts to a death sentence.
Progress
60% Bias Score
Spain's New Public Proton Therapy Network Funded by Amancio Ortega Foundation
The Amancio Ortega Foundation is funding a network of ten public proton therapy centers across Spain, starting with Santiago's center, projected to open in 2026, treating around 250 patients yearly, sparking debate on private funding in public healthcare.
Spain's New Public Proton Therapy Network Funded by Amancio Ortega Foundation
The Amancio Ortega Foundation is funding a network of ten public proton therapy centers across Spain, starting with Santiago's center, projected to open in 2026, treating around 250 patients yearly, sparking debate on private funding in public healthcare.
Progress
48% Bias Score
Two-Week Breast Cancer Test Predicts Recurrence, Personalizes Treatment
A new test, after two weeks of hormone therapy, identifies breast cancer patients (6% of 213 studied) whose Luminal B tumors don't change subtype, indicating a need for intensive treatment; this impacts around 200,000 ER-positive, HER2-positive breast cancer cases globally yearly.
Two-Week Breast Cancer Test Predicts Recurrence, Personalizes Treatment
A new test, after two weeks of hormone therapy, identifies breast cancer patients (6% of 213 studied) whose Luminal B tumors don't change subtype, indicating a need for intensive treatment; this impacts around 200,000 ER-positive, HER2-positive breast cancer cases globally yearly.
Progress
36% Bias Score
Russia Spends 16.2 Billion Rubles on Non-Protocol Medications in 2024
In 2024, Russia spent 16.2 billion rubles on medications outside official treatment protocols, with significant amounts allocated to homeopathy and herbal remedies in regions including Yakutia, Udmurtia, and Chechnya, justified by individual needs and medical decisions despite the availability of st...
Russia Spends 16.2 Billion Rubles on Non-Protocol Medications in 2024
In 2024, Russia spent 16.2 billion rubles on medications outside official treatment protocols, with significant amounts allocated to homeopathy and herbal remedies in regions including Yakutia, Udmurtia, and Chechnya, justified by individual needs and medical decisions despite the availability of st...
Progress
48% Bias Score
Substandard Cancer Drugs Found in Four African Countries
A study in The Lancet Global Health found that 17% of nearly 200 cancer drugs tested in hospitals and pharmacies across Ethiopia, Kenya, Malawi, and Cameroon had incorrect active ingredient levels, highlighting the need for improved pharmaceutical regulation and testing technologies in sub-Saharan A...
Substandard Cancer Drugs Found in Four African Countries
A study in The Lancet Global Health found that 17% of nearly 200 cancer drugs tested in hospitals and pharmacies across Ethiopia, Kenya, Malawi, and Cameroon had incorrect active ingredient levels, highlighting the need for improved pharmaceutical regulation and testing technologies in sub-Saharan A...
Progress
36% Bias Score
Substandard Cancer Drugs Found in Four African Countries
A study published in The Lancet Global Health found that 17% of nearly 200 cancer drugs sampled across hospitals and pharmacies in Ethiopia, Kenya, Malawi, and Cameroon contained incorrect active ingredient levels, highlighting a critical gap in pharmaceutical regulation and access to quality health...
Substandard Cancer Drugs Found in Four African Countries
A study published in The Lancet Global Health found that 17% of nearly 200 cancer drugs sampled across hospitals and pharmacies in Ethiopia, Kenya, Malawi, and Cameroon contained incorrect active ingredient levels, highlighting a critical gap in pharmaceutical regulation and access to quality health...
Progress
24% Bias Score
Showing 13 to 24 of 171 results